UnknownPHASE1, PHASE2NCT04009473
Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
Studying Fragile X-associated primary ovarian insufficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Forever Young d.o.o.
- Principal Investigator
- Aleksandar Ljubic, MD, PhDMedigroup, Belgrade, Serbia
- Intervention
- SEGOVA procedure(combination_product)
- Enrollment
- 100 enrolled
- Eligibility
- 25 years · FEMALE
- Timeline
- 2019 – 2021
Study locations (3)
- Saint James Hospital Malta, Sliema, Malta
- Re-medika Hospital, Skopje, Macedonia, North Macedonia
- Medigroup Health System, Jevremova hospital, Belgrade, Serbia
Collaborators
Medigroup Health System, Jevremova hospital · Saint James Hospital Malta · Re-medika Hospital Skoplje
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04009473 on ClinicalTrials.gov